Robert D. Carlson

Chimeric Ad5.F35 vector evades anti-adenovirus serotype 5 neutralization opposing GUCY2C-targeted antitumor immunity

S. Waldman, Jagmohan Singh, Trevor R Baybutt, 2020, Journal for ImmunoTherapy of Cancer.

Talkin’ Toxins: From Coley’s to Modern Cancer Immunotherapy

J. Flickinger, A. Snook, Robert D. Carlson, 2020, Toxins.

Chimeric adenoviral (Ad5.F35) and listeria vector prime-boost immunization is safe and effective for cancer immunotherapy

J. Flickinger, S. Waldman, Trevor R Baybutt, 2022, npj Vaccines.

T-Cell Responses to Immunodominant Listeria Epitopes Limit Vaccine-Directed Responses to the Colorectal Cancer Antigen, Guanylyl Cyclase C

J. Flickinger, S. Waldman, A. Snook, 2022, Frontiers in Immunology.

Evaluation of CAR-T cell cytotoxicity: Real-time impedance-based analysis.

Trevor R Baybutt, A. Snook, Robert D. Carlson, 2022, Methods in cell biology.

Targeting gastrointestinal cancers with chimeric antigen receptor (CAR)-T cell therapy

A. Snook, Ross E Staudt, Robert D Carlson, 2022, Cancer biology & therapy.

Mobilizing Toxins for Cancer Treatment: Historical Perspectives and Current Strategies

A. Snook, Robert D Carlson, Jessica Kopenhaver, 2020, Toxins.